Technology, economy and science transform the battle against malaria
February, 2013
Two critical moments in the battle against malaria came in 2001. First, Novartis introduced the first fixed-dose artemisinin-based combination therapy, or ACT. Later that year, Novartis and the World Health Organization (WHO) joined forces to provide ACTs without profit to public health systems in developing countries. This landmark agreement came at a time when public-private partnerships were still largely untested.
The initial goal of the Novartis Malaria Initiative was to deliver two million antimalarial treatments within four years. It long ago surpassed that goal, and over 500 million treatments have been delivered since 2001, contributing to a significant reduction of the death toll from malaria......
No comments:
Post a Comment